Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol To Focus On Paraplatin For Oncology Growth; UFT Review Delayed

Executive Summary

Bristol-Myers Squibb is looking to Paraplatin (carboplatin) to lead oncology growth in the wake of a court decision opening the door to generic competition for its Taxol (paclitaxel) franchise.

You may also be interested in...



Bristol Taxol Exclusivity Continues, Thanks To ABI Cremophor-Free Patent

Bristol-Myers Squibb's latest extension to the exclusivity for Taxol depends on continued rulings against the company in patent litigation in the Los Angeles federal court.

Bristol Taxol Exclusivity Continues, Thanks To ABI Cremophor-Free Patent

Bristol-Myers Squibb's latest extension to the exclusivity for Taxol depends on continued rulings against the company in patent litigation in the Los Angeles federal court.

Bristol UFT/Orzel

NDAs for UFT (tegafur/uracil) capsules for use with leucovorin in the first-line treatment of advanced colorectal cancer and Orzel (UFT capsules packaged with leucovorin tablets) are withdrawn. At a March 3 securities analyst conference, Bristol had said FDA's review was likely to be delayed (1"The Pink Sheet" March 13, p. 27). Bristol will refile the applications after FDA examines new data analyses

Related Content

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel